Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 1
2007 4
2009 5
2010 4
2011 3
2012 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [Corporate Author]
Page 1
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Teo K, et al. Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020. Am Heart J. 2004. PMID: 15215792 Clinical Trial.
OBJECTIVES: Primary objectives of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) are to determine if the combination of the ARB telmisartan and the ACE …
OBJECTIVES: Primary objectives of the ONgoing Telmisartan Alone and in Combination with Ramipril Globa …
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M, Baumhäkel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, Koon T; ONTARGET/TRANSCEND ED-Investigators. Böhm M, et al. Am Heart J. 2007 Jul;154(1):94-101. doi: 10.1016/j.ahj.2007.03.024. Am Heart J. 2007. PMID: 17584560 Clinical Trial.
No significant associations were observed for cholesterol levels, hypertension, and smoking status as well as current treatment with angiotensin-converting enzyme inhibitors, angiotensin I antagonists, diuretics, beta-blockers, or calcium-channe …
No significant associations were observed for cholesterol levels, hypertension, and smoking status as well as current treatment with angi …
Telmisartan and cardioprotection.
Akhrass PR, McFarlane SI. Akhrass PR, et al. Vasc Health Risk Manag. 2011;7:677-83. doi: 10.2147/VHRM.S9447. Epub 2011 Nov 15. Vasc Health Risk Manag. 2011. PMID: 22140319 Free PMC article. Review.
As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions, as rev …
As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and …
Lessons learned from the ONTARGET and TRANSCEND trials.
Basile J. Basile J. Curr Atheroscler Rep. 2009 Sep;11(5):371-6. doi: 10.1007/s11883-009-0056-0. Curr Atheroscler Rep. 2009. PMID: 19664381 Review.
Cardiovascular disease (CVD) accounts for one of every three deaths in the United States. ...Thus, interrupting or blocking the RAAS has become a key component in the treatment of hypertension and other cardiovascular conditions. The role of angiotensin …
Cardiovascular disease (CVD) accounts for one of every three deaths in the United States. ...Thus, interrupting or blocking th …
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Böhm M, et al. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15. Circulation. 2010. PMID: 20231536 Clinical Trial.
We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with …
We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin …
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
Diener HC. Diener HC. J Hypertens Suppl. 2009 Jul;27(5):S31-6. doi: 10.1097/01.hjh.0000357906.60778.7f. J Hypertens Suppl. 2009. PMID: 19587553 Review.
The PReventiOn regimen For Effectively avoiding Second Strokes (PRoFESS) trial, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized …
The PReventiOn regimen For Effectively avoiding Second Strokes (PRoFESS) trial, ONgoing Telmisartan Alone and in …
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.
Ram CV. Ram CV. Vasc Health Risk Manag. 2011;7:315-9. doi: 10.2147/VHRM.S15787. Epub 2011 May 15. Vasc Health Risk Manag. 2011. PMID: 21633521 Free PMC article. Review.
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and …
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial …
The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P. Sleight P. Acta Diabetol. 2005 Apr;42 Suppl 1:S50-6. doi: 10.1007/s00592-005-0181-3. Acta Diabetol. 2005. PMID: 15868120 Clinical Trial.
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) is designed to clarify whether an ARB (telmisartan), an ACE inhibitor (ramipril) or a combination …
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial …
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL. Cowan BR, et al. Clin Res Cardiol. 2009 Jul;98(7):421-33. doi: 10.1007/s00392-009-0014-4. Epub 2009 Apr 4. Clin Res Cardiol. 2009. PMID: 19347385 Clinical Trial.
BACKGROUND: The ONTARGET and TRANSCEND clinical trials were designed to investigate the cardioprotective effects of telmisartan 80 mg and ramipril 10 mg, alone and in combination, in patients at high risk of cardiovascula …
BACKGROUND: The ONTARGET and TRANSCEND clinical trials were designed to investigate the cardioprotective effects …
The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice.
González-Juanatey JR. González-Juanatey JR. J Hypertens Suppl. 2009 Jun;27(2):S32-5. doi: 10.1097/01.hjh.0000354518.90321.bb. J Hypertens Suppl. 2009. PMID: 19491621
In patients with arterial hypertension and/or high cardiovascular risk, including patients with diabetes, chronic ischemic heart disease and kidney disease, the risk of heart failure decreases with blood pressure reduction and the use of drugs that inhibit th …
In patients with arterial hypertension and/or high cardiovascular risk, including patients with diabetes, chronic ischemic heart d …
23 results